---
figid: PMC6795182__en.2019-00410f1
figtitle: Cluster-1, cluster-2, and cluster-3, with molecular-targeted therapeutic
  options
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC6795182
filename: en.2019-00410f1.jpg
figlink: pmc/articles/PMC6795182/figure/fig1/
number: F1
caption: 'Cluster-1, cluster-2, and cluster-3, with molecular-targeted therapeutic
  options. Cluster-1: The pseudo-hypoxic signaling cluster includes mutations in genes
  encoding for hypoxia-inducible factor 2-α (HIF2A), Krebs-cycle enzymes such as succinate
  dehydrogenase subunits [SDHx (SDHA, SDHB, SDHC, SDHD)], succinate dehydrogenase
  complex assembly factor-2 (SDHAF2), fumarate hydratase (FH), malate dehydrogenase
  2 (MDH2), and isocitrate dehydrogenase (IDH), and including von Hippel–Lindau tumor
  suppressor (VHL) and egl-9 prolyl hydroxylase 1 and 2 (EGLN1/2). Cluster-2: The
  kinase signaling cluster comprises mutations in the rearranged-during-transfection
  (RET) proto-oncogene, neurofibromin 1 (NF1) tumor suppressor, H-RAS and K-RAS proto-oncogenes,
  transmembrane protein 127 (TMEM127), and Myc-associated factor X (MAX). Receptor
  tyrosine kinases (among others, RET, VEGFR, c-met) activate insulin receptor substrate
  1 (IRS-1), which recruits the phosphatidylinositol-3-kinase (PI3K). PI3K activates
  AKT, which inhibits tuberous sclerosis proteins 1/2 (TSC1/2), leading to disinhibition/activation
  of the mammalian target of rapamycin (mTORC1); mTORC1 phosphorylates and activates
  various proteins, including p70S6 kinase (p70S6K), by which p70S6 is phosphorylated.
  Activated p70S6 promotes cell growth, proliferation, cell survival, and leads, among
  other effects, to the protein synthesis of HIF-1α, which favors angiogenesis [VEGF/platelet-derived
  growth factor (PDGF)] transcription, among others], invasion, and metastasis under
  hypoxic or pseudo-hypoxic conditions. AKT also inhibits glycogen synthase kinase
  3 (GSK3). Persistent activation of PI3K leads to feedback downregulation of IRS-1,
  which may lead to GSK3 disinhibition/activation. The RAS/RAF/ERK pathway is also
  activated by tyrosine kinases (RET, among others) and activates mTORC1. NF1 mutations
  lead to disinhibition/activation of RAS. TMEM127 mutations lead to disinhibition/activation
  of mTORC1. The tumor suppressor MAX antagonizes Myc-dependent cell survival, proliferation,
  and angiogenesis: mutations lead to increased cell proliferation and angiogenesis.
  Cluster-3: The Wnt signaling cluster comprises somatic mutations in cold shock domain
  containing E1 (CSDE1) and the mastermind-like transcriptional coactivator 3 (MAML3)
  fusion genes.     , pheochromocytoma-promoting loss-of-function mutation of a tumor
  suppressor gene; ○, pheochromocytoma-promoting gain-of-function mutation of a proto-oncogene.
  ↑, increase/upregulation; ⊥, inhibition; ↓, activation.'
papertitle: Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma
  Models Including Human Tumor Cultures.
reftext: Maria Fankhauser, et al. Endocrinology. 2019 Nov;160(11):2600-2617.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9463632
figid_alias: PMC6795182__F1
figtype: Figure
redirect_from: /figures/PMC6795182__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6795182__en.2019-00410f1.html
  '@type': Dataset
  description: 'Cluster-1, cluster-2, and cluster-3, with molecular-targeted therapeutic
    options. Cluster-1: The pseudo-hypoxic signaling cluster includes mutations in
    genes encoding for hypoxia-inducible factor 2-α (HIF2A), Krebs-cycle enzymes such
    as succinate dehydrogenase subunits [SDHx (SDHA, SDHB, SDHC, SDHD)], succinate
    dehydrogenase complex assembly factor-2 (SDHAF2), fumarate hydratase (FH), malate
    dehydrogenase 2 (MDH2), and isocitrate dehydrogenase (IDH), and including von
    Hippel–Lindau tumor suppressor (VHL) and egl-9 prolyl hydroxylase 1 and 2 (EGLN1/2).
    Cluster-2: The kinase signaling cluster comprises mutations in the rearranged-during-transfection
    (RET) proto-oncogene, neurofibromin 1 (NF1) tumor suppressor, H-RAS and K-RAS
    proto-oncogenes, transmembrane protein 127 (TMEM127), and Myc-associated factor
    X (MAX). Receptor tyrosine kinases (among others, RET, VEGFR, c-met) activate
    insulin receptor substrate 1 (IRS-1), which recruits the phosphatidylinositol-3-kinase
    (PI3K). PI3K activates AKT, which inhibits tuberous sclerosis proteins 1/2 (TSC1/2),
    leading to disinhibition/activation of the mammalian target of rapamycin (mTORC1);
    mTORC1 phosphorylates and activates various proteins, including p70S6 kinase (p70S6K),
    by which p70S6 is phosphorylated. Activated p70S6 promotes cell growth, proliferation,
    cell survival, and leads, among other effects, to the protein synthesis of HIF-1α,
    which favors angiogenesis [VEGF/platelet-derived growth factor (PDGF)] transcription,
    among others], invasion, and metastasis under hypoxic or pseudo-hypoxic conditions.
    AKT also inhibits glycogen synthase kinase 3 (GSK3). Persistent activation of
    PI3K leads to feedback downregulation of IRS-1, which may lead to GSK3 disinhibition/activation.
    The RAS/RAF/ERK pathway is also activated by tyrosine kinases (RET, among others)
    and activates mTORC1. NF1 mutations lead to disinhibition/activation of RAS. TMEM127
    mutations lead to disinhibition/activation of mTORC1. The tumor suppressor MAX
    antagonizes Myc-dependent cell survival, proliferation, and angiogenesis: mutations
    lead to increased cell proliferation and angiogenesis. Cluster-3: The Wnt signaling
    cluster comprises somatic mutations in cold shock domain containing E1 (CSDE1)
    and the mastermind-like transcriptional coactivator 3 (MAML3) fusion genes.     ,
    pheochromocytoma-promoting loss-of-function mutation of a tumor suppressor gene;
    ○, pheochromocytoma-promoting gain-of-function mutation of a proto-oncogene. ↑,
    increase/upregulation; ⊥, inhibition; ↓, activation.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pdgfrb
  - Egfr
  - Egf
  - Vegfa
  - Maml3
  - Nf1
  - Mdh2
  - Irs1
  - Ctnnb1
  - fh
  - Pik3r1
  - Csde1
  - Akt1
  - Ephb2
  - Mapk1
  - Tsc2
  - Tsc1
  - Gsk3b
  - Max
  - Myc
  - Nol3
  - Egln2
  - Egln1
  - Tmem127
  - Eif4e
  - Vhl
  - Hdac1
  - Hdac1-ps
  - Epas1
  - Slc1a3
  - Slc2a1
  - Parp1
  - Cdkn1a
  - Nsg1
  - Tpt1
  - Tceal1
  - ras
  - Hras
  - Kras
  - Rem1
  - Hif1a
  - PDGFRB
  - PDGFRA
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - KDR
  - FLT1
  - FLT4
  - EGFR
  - EGF
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - MAML3
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - NF1
  - MDH2
  - IRS1
  - CTNNB1
  - FH
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - CSDE1
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - MAPK1
  - MAPK3
  - TSC2
  - TSC1
  - CCL26
  - GSK3A
  - GSK3B
  - IDH1
  - IDH2
  - RPTOR
  - MAX
  - MYC
  - ARNT
  - ARNT2
  - BMAL1
  - EGLN2
  - RAB4B-EGLN2
  - EGLN1
  - TMEM127
  - EIF4E
  - VHL
  - HIF1A
  - EPAS1
  - HIF3A
  - HECTD4
  - HDAC1
  - SLC2A1
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - HRAS
  - KRAS
  - NRAS
  - mid
  - btl
  - htl
  - Pvr
  - bnl
  - Pvf1
  - Pvf2
  - Pvf3
  - Wnt5
  - Wnt4
  - wg
  - Wnt2
  - Mdh1
  - arm
  - CycE
  - cyc
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Erk7
  - rl
  - sd
  - gig
  - sgg
  - Idh
  - Idh3b
  - Crtc
  - mof
  - eIF4E1
  - sima
  - achi
  - EcR
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Glut1
  - Parp
  - dap
  - Ras64B
  - Ras85D
  - Tyrosine
  - cabozantinib
  - sunitinib
  - malate
  - oxaloacetate
  - citrate
  - 12-hydroxy
  - fumarate
  - isocitrate
  - everolimus
  - succinate
  - ketoglutarate
  - temozolomide
  - VHL
  - HIF-1a Cluster 1 Cluster 2
---
